Linköping, Sweden – A combination of only 11 proteins can predict long-term disability outcomes in multiple sclerosis (MS) for different individuals. The identified proteins could be used to tailor treatments to the individual based on the expected severity of the disease. The study, led by researchers at Linköping University in...
Latest News
It’s a warm Tuesday afternoon and the Shalvey family is enjoying the sun out on their patio while their dogs, Sam and Jerry, run around the yard. Add in their white picket fence and the image is idyllic – but not uncommon for Bill and Lynne and their two daughters,...
Tokyo, Japan – Sarcoidosis is a complex inflammatory disease that causes the harmful accumulation of tiny clumps of cells called granulomas in the body. In most cases, sarcoidosis manifests in the lungs and lymph nodes. However, in approximately 10% of patients, the heart is affected; this condition is known as...
BOSTON, Mass. – About eight million people live with Type 1 diabetes (T1D) worldwide, a chronic autoimmune condition in which the body attacks and destroys its own insulin-producing β-cells (pronounced “beta”) in the pancreas, leading to a lack of insulin and inability to regulate blood sugar. It’s not known why...
Matsumoto, Japan – Early detection and treatment of hereditary transthyretin-related amyloidosis via genetic counseling are crucial. Yet, not all at-risk individuals seek genetic counseling, and management for presymptomatic carriers remains unclear. To tackle these knowledge gaps, a research team from Japan conducted a retrospective study on over 200 people who...
CLONMEL, Ireland – Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, has announced today that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a lifesaving treatment that is often in shortage and the...
CLONMEL, Ireland – Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, announces the appointment of Chief Commercial Officer Nicholas Holsman, a highly experienced U.S. industry executive with in-depth experience in scaling oncology & specialty pharma enterprises. Shorla specializes in developing innovative oncology drugs, with a focus on orphan and pediatric cancers....
– Favorable reimbursement policies across many countries are estimated to drive the short bowel syndrome market during the forecast period – High cost of parenteral nutrition will boost the demand for SBS drugs extensively, eventually increasing the growth rate of the global market ALBANY – Transparency Market Research, New York: The growing prevalence...
Compared with standard whole-body magnetic resonance imaging (WBMRI), a short WBMRI protocol may reduce the length of MRI tests, while maintaining high sensitivity and specificity, among patients with multiple myeloma (MM) undergoing diagnostic testing, according to research published in Diagnostics. MM is the second-most common hematologic cancer, following non-Hodgkin lymphomas, and...
PRINCETON, N.J. & TOKYO & WALTHAM, Mass. — Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of...